Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Jaclyn A BiegelDepartment of Pathology, Children's Hospital Los Angeles and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE)UL1TR002378 · NCATS · EMORY UNIVERSITY · PI Andres J Garcia, Elizabeth O. Ofili · 2017 to 2026
$92.1M
Weill Cornell/Rockefeller/Sloan-Kettering MST ProgramT32GM007739 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI HSU, KATHARINE C · 1985 to 2023
$51.1M
Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5M
PREDOCTORAL TRAINING PROGRAM IN GENETICST32GM008490 · NIGMS · EMORY UNIVERSITY · PI BOSS, JEREMY M. · 1993 to 2022
$8.0M
Single-cell epigenomic phenotyping of IMPC-generated mouse lines lacking chromatin regulatorsR01HD102534 · NICHD · EMORY UNIVERSITY · PI GORKIN, DAVID USCHER · 2021 to 2025
$3.4M
Integrated omics analysis of clonal hematopoiesis and cardiovascular disease risk in TOPMedR01HL168894 · NHLBI · EMORY UNIVERSITY · PI Karen Conneely, Pradeep Natarajan · 2023 to 2026
$2.6M
Medical Scientist Training ProgramT32GM156741 · NIGMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Talene Alene Yacoubian · 2025 to 2026
$2.5M
Elucidating the mechanisms of protein secretion across the outer membrane by bacterial autotransportersR01GM148586 · NIGMS · GEORGIA INSTITUTE OF TECHNOLOGY · PI James C. Gumbart · 2023 to 2026
$1.8M
Functional consequences of SMARCB1 variantsR01CA289761 · NCI · EMORY UNIVERSITY · PI Andrew L Hong · 2025 to 2026
$1.0M
The role of DPF2 stability in SMARCB1-deficient cancersF31CA278008 · NCI · EMORY UNIVERSITY · PI GARRETT COOPER · 2023 to 2026
$118k
American Cancer Society (American Cancer Society, Inc.) MRSG-18-202-01NCI NIH HHS R01 CA289761NHLBI NIH HHS R01 HL168894NICHD NIH HHS R01 HD102534NIGMS NIH HHS R01 GM148586U.S. Department of Defense (United States Department of Defense) HT9425-23-0609U.S. Department of Defense (United States Department of Defense) W81XWH1910281U.S. Department of Health & Human Services | National Institutes of Health (NIH) UL1TR002378U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) R01HD102534U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) F31CA278008U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) P30CA138292U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA289761U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) R01-GM148586U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) T32GM007739U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) T32GM008490U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) T32GM156741
6 · The paper itself
Abstract
Chromatin remodeling complexes, such as the SWItch/Sucrose Non-Fermentable (SWI/SNF) complex, play key roles in regulating gene expression by modulating nucleosome positioning. The core subunit SMARCB1 is essential for these functions, as it anchors the complex to the nucleosome acidic patch, enabling effective chromatin remodeling. While biallelic inactivation of SMARCB1 is a hallmark of several aggressive pediatric malignancies, the functional implication of missense mutations is not fully understood. Current diagnostic approaches focus on detecting the presence or absence of SMARCB1 by immunohistochemistry often without consideration of mutation status. Here, we present a comprehensive deep mutational scanning of SMARCB1, encompassing 8418 alterations, to assess their functional impact. We show that RPT2 missense mutations disrupt SMARCB1 antiproliferation function by destabilizing the SWI/SNF complex and impairing chromatin remodeling and transcriptional regulation comparable to nonsense mutations. These functional defects occur despite maintaining detectable protein expression thereby challenging current diagnostic reliance on IHC. These findings provide deeper understanding of the role of SMARCB1 in chromatin remodeling and cancer biology, highlighting limitations of mutation classification approaches.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
SMARCB1 missense mutants disrupt SWI/SNF complex stability and remodeling activity. · full record | OpenQuestion